原始来源记录
状态: COMPLETED → TERMINATED; primary_completion: 2016-12-20 → 2016-12-19; completion: 2016-12-20 → 2016-12-19; why_stopped: → 赞助商决定停止 lebrikizumab 用于哮喘治疗的开发。; primary_outcomes: ['Relative Change From Baseline in Daily OCS Dose at Week 44'] → ['从基线到第 44 周每日口服皮质类固醇 (OCS) 剂量的百分比变化']; countries: {'total_sites': 71, 'us_sites': 9} → {'total_sites': 45, 'us_sites': 2}